The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer, Africa CDC Strikes COVID-19 Antiviral Pact According to a Reuters report , Africa's public health body signed a memorandum of understanding with Pfizer Inc  (NYSE: PFE ), allowing African countries to access Paxlovid at cost.  The news comes just a few months after researchers with the Drugs for Neglected Diseases Initiative reported that they were denied access to Paxlovid for use in a large study in 10 African countries that aim to find treatments for mild to moderate COVID-19. RVL Pharma Sees Q2 Upneeq Sales of Around $8M RVL Pharmaceuticals plc  (NASDAQ: RVLP ) announced preliminary Q2 FY22 sales from Upneeq of $8.4 million , up 42% sequentially. The company also announced that from February through June of 2022, it had received orders from approximately 2,200 cumulative unique medical aesthetics practices.  RVL Pharma also reaffirmed its Q4 Upneeq sales guidance of $20 - $25 million. Dare Biosciences Secures Grant Payment Of Around $8M From Bill & Melinda Gates Foundation Daré Bioscience Inc  (NASDAQ: DARE ) received a grant payment of approximately $7.96 million  from the ... Full story available on Benzinga.com